This article was originally published in The Gray Sheet
Executive SummaryVagus nerve stimulation system developer raises $45 mil. in a private placement of 2.5 mil. common shares at $18 each. Proceeds will be used to fund ongoing and future clinical trials in depression, obesity and anxiety, the firm reports Feb. 14. Company's 21-center, 210-patient U.S. pivotal study for depression has enrolled 136 patients to date. Pilot studies in obesity and Alzheimer's are underway, and the firm also has an approved IDE for a 30-patient, four-center pilot study set to begin in fiscal 2001 of left cervical vagus nerve stimulation for three major anxiety disorders. US Bancorp Piper Jaffray acted as placement agent for the financing
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.